OBJECTIVE: We aimed to analyze the association between morphine and in-hospital outcomes in invasively managed ST elevation myocardial infarction (STEMI) and non-ST elevation acute coronary syndrome (NSTE-ACS) patients. BACKGROUND: Morphine is commonly used for analgesia in the setting of acute coronary syndromes (ACS); however, recently its utility in ACS has come under closer scrutiny. METHODS: We identified all STEMI and NSTE-ACS patients undergoing coronary angiogram +/- percutaneous intervention between January 2009 and July 2016 in our center and recorded patient characteristics and inpatient outcomes. RESULTS: Overall, 3027 patients were examined. Overall, STEMI patients who received morphine had no difference in in-hospital mortality [4.18% vs. 7.54%, odds ratio (OR): 0.36, P = 0.19], infarct size (mean troponin level 0.75 ng/mL vs. 1.29 ng/mL, P = 0.32) or length of hospital stay (P = 0.61). The NSTE-ACS patients who received morphine had a longer hospital stay (mean 6.58 days vs. 4.78 days, P < 0.0001) and larger infarct size (mean troponin 1.16 ng/mL vs. 0.90 ng/mL, P = 0.02). Comparing matched patients, the use of morphine was associated with larger infarct size (mean troponin 1.14 ± 1.92 ng/mL vs. 0.83 ± 1.49 ng/mL, P = 0.01), longer hospital stay (6.5 ± 6.82 days vs. 4.89 ± 5.36 days, P = 0.004) and a trend towards increased mortality (5% vs. 2%, OR: 2.55, P = 0.06) in NSTE-ACS patients but morphine did not affect outcomes in the propensity matched STEMI patients. CONCLUSION: In a large retrospective study, morphine was associated with larger infarct size, a longer hospital stay and a trend towards increased mortality in invasively managed NSTE-ACS patients even after adjustment for clinical characteristics.
OBJECTIVE: We aimed to analyze the association between morphine and in-hospital outcomes in invasively managed ST elevation myocardial infarction (STEMI) and non-ST elevation acute coronary syndrome (NSTE-ACS) patients. BACKGROUND:Morphine is commonly used for analgesia in the setting of acute coronary syndromes (ACS); however, recently its utility in ACS has come under closer scrutiny. METHODS: We identified all STEMI and NSTE-ACS patients undergoing coronary angiogram +/- percutaneous intervention between January 2009 and July 2016 in our center and recorded patient characteristics and inpatient outcomes. RESULTS: Overall, 3027 patients were examined. Overall, STEMI patients who received morphine had no difference in in-hospital mortality [4.18% vs. 7.54%, odds ratio (OR): 0.36, P = 0.19], infarct size (mean troponin level 0.75 ng/mL vs. 1.29 ng/mL, P = 0.32) or length of hospital stay (P = 0.61). The NSTE-ACS patients who received morphine had a longer hospital stay (mean 6.58 days vs. 4.78 days, P < 0.0001) and larger infarct size (mean troponin 1.16 ng/mL vs. 0.90 ng/mL, P = 0.02). Comparing matched patients, the use of morphine was associated with larger infarct size (mean troponin 1.14 ± 1.92 ng/mL vs. 0.83 ± 1.49 ng/mL, P = 0.01), longer hospital stay (6.5 ± 6.82 days vs. 4.89 ± 5.36 days, P = 0.004) and a trend towards increased mortality (5% vs. 2%, OR: 2.55, P = 0.06) in NSTE-ACS patients but morphine did not affect outcomes in the propensity matched STEMI patients. CONCLUSION: In a large retrospective study, morphine was associated with larger infarct size, a longer hospital stay and a trend towards increased mortality in invasively managed NSTE-ACS patients even after adjustment for clinical characteristics.
Authors: Suzanne de Waha; Ingo Eitel; Steffen Desch; Georg Fuernau; Philipp Lurz; Daniel Urban; Gerhard Schuler; Holger Thiele Journal: Clin Res Cardiol Date: 2015-03-01 Impact factor: 5.460
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Trip J Meine; Matthew T Roe; Anita Y Chen; Manesh R Patel; Jeffrey B Washam; E Magnus Ohman; W Frank Peacock; Charles V Pollack; W Brian Gibler; Eric D Peterson Journal: Am Heart J Date: 2005-06 Impact factor: 4.749
Authors: J Herlitz; A Hjalmarson; S Holmberg; K Swedberg; F Waagstein; A Waldenström; J Waldenström Journal: Cardiology Date: 1984 Impact factor: 1.869
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Jacek Kubica; Piotr Adamski; Małgorzata Ostrowska; Joanna Sikora; Julia Maria Kubica; Wiktor Dariusz Sroka; Katarzyna Stankowska; Katarzyna Buszko; Eliano Pio Navarese; Bernd Jilma; Jolanta Maria Siller-Matula; Michał Piotr Marszałł; Danuta Rość; Marek Koziński Journal: Eur Heart J Date: 2015-10-21 Impact factor: 29.983
Authors: Piotr Adamski; Katarzyna Buszko; Joanna Sikora; Piotr Niezgoda; Tomasz Fabiszak; Małgorzata Ostrowska; Malwina Barańska; Aleksandra Karczmarska-Wódzka; Eliano Pio Navarese; Jacek Kubica Journal: Sci Rep Date: 2019-03-08 Impact factor: 4.379
Authors: Himawan Fernando; Ziad Nehme; Karlheinz Peter; Stephen Bernard; Michael Stephenson; Janet Bray; Peter Cameron; Andris Ellims; Andrew Taylor; David M Kaye; Karen Smith; Dion Stub Journal: Open Heart Date: 2020-07
Authors: Himawan Fernando; Ziad Nehme; Karlheinz Peter; Stephen Bernard; Michael Stephenson; Janet E Bray; Paul S Myles; Romi Stub; Peter Cameron; Andris H Ellims; Andrew J Taylor; David M Kaye; Karen Smith; Dion Stub Journal: Int J Cardiol Heart Vasc Date: 2021-11-08